Diabetic Macular Edema – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Diabetic Macular Edema – Drugs In Development, 2023’, provides an overview of the Diabetic Macular Edema pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema
- The report reviews pipeline therapeutics for Diabetic Macular Edema by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diabetic Macular Edema therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Macular Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diabetic Macular Edema
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
3SBio Inc4D Molecular Therapeutics Inc
Aadi Bioscience Inc
Abpro Corp
AffaMed Therapeutics US Inc
AiViva BioPharma Inc
Alcon Inc
Alimera Sciences Inc
Allegro Ophthalmics LLC
Allgenesis Biotherapeutics Inc
AmMax Bio Inc
ANBITION Srl
AntlerA Therapeutics Inc
Apexian Pharmaceuticals Inc
Araim Pharmaceuticals Inc
Arctic Vision Shanghai Biotechnology Co Ltd
Ascentage Pharma Group International
AsclepiX Therapeutics Inc
Ashvattha Therapeutics LLC
AskGene Pharma Inc
Aviceda Therapeutics Inc
Avirmax Inc
Bausch & Lomb Inc
Beijing StarMab BioMed Technology Ltd
BetaStem Therapeutics Inc
Bio-Thera Solutions Ltd
BioCryst Pharmaceuticals Inc
Boehringer Ingelheim International GmbH
Cell Care Therapeutics Inc
Celltrion Inc
Celon Pharma SA
Chengdu Kanghong Pharmaceuticals Group Co Ltd
China Medical System Holdings Ltd
Chiome Bioscience Inc
Chongqing Kerun Biopharm R & D Co Ltd
Clearside BioMedical Inc
Clonz Biotech Pvt Ltd
CTx Operations Inc
Daewoong Pharmaceutical Co Ltd
Drive Therapeutics LLC
Elasmogen Ltd
Eluminex Biosciences Ltd
Everglades Biopharma LLC
Excitant Therapeutics LLC
Exonate Ltd
EyePoint Pharmaceuticals Inc
Eyevensys SAS
F. Hoffmann-La Roche Ltd
Frontera Therapeutics Inc
Gene Signal International SA
Genentech USA Inc
Glaukos Corp
Hanmi Pharmaceuticals Co Ltd
Huabo Biopharm (Shanghai) Co Ltd
Huadong Medicine Co Ltd
Ikarovec Ltd
Inflammasome Therapeutics Inc
Inflammx Therapeutics Inc
Ingenia Therapeutics Inc
Innovent Biologics Inc
Isarna Therapeutics GmbH
Jecho Biopharmaceuticals Co Ltd
KALA BIO Inc
Kalos Therapeutics Inc
Kalvista Pharmaceuticals Inc
Kanaph Therapeutics Inc
Kodiak Sciences Inc
Kubota Vision Inc
Kyowa Kirin Co Ltd
Laboratorios Salvat SA
Laboratorios Sophia SA de CV
Lan-yi Therapeutics Ltd
Luye Pharma Group Ltd
Mabion SA
MabTics
Mabwell Shanghai Bioscience Co Ltd
Molecular Partners AG
Neortesbio Inc
NeuMedics Inc
NeuVasQ Biotechnologies
Novartis AG
Novelty Nobility Inc
Noveome Biotherapeutics Inc
Oak Hill Bio Inc
Ocular Therapeutix Inc
Oculis Holding AG
Ocumension Therapeutics Co Ltd
OcuNexus Therapeutics Inc
Ocuphire Pharma Inc
OcuTerra Therapeutics Inc
Opthea Ltd
Outlook Therapeutics Inc
Oxular Ltd
Phanes Therapeutics Inc
PharmAbcine Inc
Pleryon Therapeutics Ltd
Profarma
Qilu Pharmaceutical Co Ltd
Rebio Technologies Ltd
Regenerate Therapeutics Inc
Regeneron Pharmaceuticals Inc
RemeGen Co Ltd
RevOpsis Therapeutics Corp
Rezolute Inc
RiniSight Inc
Ripple therapeutics Corp
Rophibio Inc
Semathera Inc
Shanghai Institute of Materia Medica Chinese Academy of Sciences
Shanghai Jing Ze Biotechnology Co Ltd
Shanghai SIMR Biotech Co Ltd
Shilpa Biologicals Pvt Ltd
Stuart Therapeutics Inc
Suzhou Stainwei Biotech Inc
Tarsier Pharma Ltd
Thea Open Innovation SASU
Theratocular Biotek Co Ltd
Theravance Biopharma Inc
Therini Bio Inc
Uni-Bio Science Group Ltd
Unity Biotechnology Inc
University of Montreal
Valitor Inc
Vall d’Hebron Institute of Research
Vantage Biosciences Ltd
Viatris Inc
Wuhan Neurophth Biological Technology Ltd
Xbrane Biopharma AB
YD Life Science Co
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd